1. SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model
- Author
-
Maria Bellenghi, Giovanna Talarico, Laura Botti, Rossella Puglisi, Claudio Tabolacci, Paola Portararo, Annamaria Piva, Giada Pontecorvi, Alessandra Carè, Mario P. Colombo, Gianfranco Mattia, and Sabina Sangaletti
- Subjects
Cancer Research ,Epithelial-Mesenchymal Transition ,Fatty Acids ,Oleic Acids ,Triple Negative Breast Neoplasms ,Disease Models, Animal ,Mice ,Tumor Microenvironment ,Genetics ,Animals ,Humans ,Osteonectin ,Molecular Biology ,Stearoyl-CoA Desaturase - Abstract
Dysregulated fatty acid metabolism interacts with oncogenic signals, thereby worsening tumor aggressiveness. The stearoyl-CoA desaturating enzymes, SCD1 and SCD5, convert of saturated fatty acids to monounsaturated fatty acids. While SCD1 is frequently overexpressed in tumor cells and has been widely studied, SCD5 has both limited expression and poor characterization. Here we evaluated, in vitro and in vivo, the effects of SCD5 overexpression in a metastatic clone of 4T1. The results showed SCD5-driven reprogramming of fatty acid metabolism, involving desaturation of stearic acid to oleic acid, which eventually blocked SPARC secretion. The latter event reduced the aggressiveness of the 4T1 subclone by decreasing the ECM deposition and reverting the Epithelial to Mesenchymal Transition (EMT) status. Variation of the fatty acid profile by SCD5-gene transduction or the direct administration oleic acid reduces the immune suppressive activity of myeloid cells and promoting granulocytic myeloid-derived suppressor cell maturation, eventually favoring T-cell activation. The less immunosuppressive microenvironment generated by SCD5 overexpression was enhanced in Sparc-KO mice, indicating that both extracellular and endogenous SPARC additively regulate myeloid cell-suppressive activities. Overall, our data sheds light on exploring the oleic acid-dependent inhibition of SPARC secretion as a possible mechanism to reduce breast cancer malignancy.
- Published
- 2022
- Full Text
- View/download PDF